Compare AMKR & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMKR | GMAB |
|---|---|---|
| Founded | 1968 | 1999 |
| Country | United States | Denmark |
| Employees | 30800 | 3088 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4B | 16.2B |
| IPO Year | 1997 | N/A |
| Metric | AMKR | GMAB |
|---|---|---|
| Price | $70.84 | $26.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $64.50 | $39.56 |
| AVG Volume (30 Days) | ★ 4.8M | 1.8M |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.47% | N/A |
| EPS Growth | ★ 4.90 | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $4,052,650,000.00 | N/A |
| Revenue This Year | $13.24 | $17.85 |
| Revenue Next Year | $9.90 | $16.04 |
| P/E Ratio | $219.97 | ★ $1.90 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.79 | $19.81 |
| 52 Week High | $79.23 | $35.43 |
| Indicator | AMKR | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 53.98 | 45.49 |
| Support Level | $40.96 | $25.34 |
| Resistance Level | $79.10 | $29.64 |
| Average True Range (ATR) | 4.40 | 0.75 |
| MACD | -1.10 | -0.02 |
| Stochastic Oscillator | 42.05 | 40.48 |
Amkor Technology Inc is a OSAT (outsourced semiconductor assembly and test) service provider. It has pioneered the outsourcing of integrated circuit (IC) packaging and test services and is a strategic manufacturing partner for the semiconductor companies, foundries, and electronics original equipment manufacturers (OEMs). The firm's products are organized into two categories namely advanced products that include flip chip, fine pitch bumping, wafer-level processing, advanced SiPs, power modules, and others, and Mainstream products that includes wirebond packaging and testing. The company derives maximum revenue from the advanced products category. The company derives majority of its revenue from Foreign states.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.